Skip to main content
Erschienen in: Acta Neurochirurgica 11/2010

01.11.2010 | Clinical Article

The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series

verfasst von: Alessandro Della Puppa, Marta Rossetto, Pietro Ciccarino, Giulia Del Moro, Antonino Rotilio, Renzo Manara, Marina Paola Gardiman, Luca Denaro, Domenico d’Avella, Renato Scienza

Erschienen in: Acta Neurochirurgica | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Carmustine (1,3-bis[2-chloroetyl]-1-nitrosurea (BCNU)) wafers are approved for the local treatment of newly diagnosed and recurrent malignant glioma. Reassuring data on both safety and efficacy of treatment have been previously reported by phase III studies. Although most of related adverse events are reported in the first few months after surgery, there is a lack in the literature of radiological data regarding this period. Few anecdotal experiences have been reported about surgical bed cyst occurrence. The aim of our study is to analyse the radiological course of patients treated with wafers implantation focusing on the relationship between radiological data, and in particular bed cyst occurrence, and safety data.

Methods

Forty-three patients affected by malignant glioma underwent surgical removal and BCNU wafers implantation at the Department of Neurosurgery of Padova from April 2007 to October 2009. Safety data were collected according to previously reported phase III studies. Patients underwent clinical and radiological evaluation (MRI) postoperatively, then before discharge, at 1 month, then every 2 months. In the study were included only patients whose both 1- and 3-month MRIs were available. Finally, 36 out of 43 patients were available for the revision.

Findings

Fifty-eight percent of patients treated with BCNU wafers presented a bed cyst of the surgical cave at the 1-month MRI. Forty-eight percent of them were symptomatic. Conversely, among patients who presented one or more adverse event (27%), bed cyst was detected in up to 90% of cases (OR 7.35), being intracranial hypertension more frequently associated (OR 7.35; p value <0.05). In general, cysts presented a benign behaviour in the sense that patients promptly improved with corticosteroid treatment, never required surgery, never reported permanent neurological deficits.

Conclusions

Surgical bed cyst occurrence in BCNU wafer-treated patients resulted more frequent than expected. Familiarity with the event is important to correctly handle a possible evolving phenomenon. However, only further larger experiences and prospective studies could reveal how the understanding of such event might be helpful to improve safety data.
Literatur
1.
Zurück zum Zitat Asher AL (2007) Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington, DC, 2007 Asher AL (2007) Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington, DC, 2007
2.
Zurück zum Zitat Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–2893CrossRefPubMed Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–2893CrossRefPubMed
3.
Zurück zum Zitat Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Clifford Schold S (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012CrossRefPubMed Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Clifford Schold S (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012CrossRefPubMed
4.
Zurück zum Zitat Dal Pan G, Butler L, Schactman M (1997) Preliminary analysis of the GLIADEL treatment protocol. Abstract presented at the ASCO Annual Meeting, Atlanta, GA, 1997 Dal Pan G, Butler L, Schactman M (1997) Preliminary analysis of the GLIADEL treatment protocol. Abstract presented at the ASCO Annual Meeting, Atlanta, GA, 1997
5.
Zurück zum Zitat Darakchiev BJ, Albright RE, Breneman JC, Warnick RE (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236–242CrossRefPubMed Darakchiev BJ, Albright RE, Breneman JC, Warnick RE (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236–242CrossRefPubMed
7.
Zurück zum Zitat Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53:220–224CrossRefPubMed Engelhard HH (2000) Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 53:220–224CrossRefPubMed
8.
Zurück zum Zitat Engelhard HH, Maher de Leon ME, Rozental JM (1998) Tumor bed cyst formation after BCNU wafer implantation. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Seattle, WA, 1998 Engelhard HH, Maher de Leon ME, Rozental JM (1998) Tumor bed cyst formation after BCNU wafer implantation. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Seattle, WA, 1998
9.
Zurück zum Zitat Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cent Eur Neurosurg Jan 8 doi:10.1055/s-0029-1242775 Giese A, Bock HC, Kantelhardt SR, Rohde V (2010) Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cent Eur Neurosurg Jan 8 doi:10.​1055/​s-0029-1242775
10.
Zurück zum Zitat Gonza´lez Vidal D (2006) The safety of Gliadel implants during the indication period in recurrent surgery in the treatment of glioblastoma multiforme [abstract]. Neurocirugıa 17:77–78 Gonza´lez Vidal D (2006) The safety of Gliadel implants during the indication period in recurrent surgery in the treatment of glioblastoma multiforme [abstract]. Neurocirugıa 17:77–78
11.
Zurück zum Zitat Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 3:246–250PubMed Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology 3:246–250PubMed
12.
Zurück zum Zitat Kleinberg LR, Weingart J, Burger P, Grossman CK, SA Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 22:1–9CrossRefPubMed Kleinberg LR, Weingart J, Burger P, Grossman CK, SA Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 22:1–9CrossRefPubMed
13.
Zurück zum Zitat LaRocca R, Glisson S, Hargis J, Petruska D, Villanueva W, Morassutti D, Horne D, Amin-Zimmerman F (2005) High-grade glioma treated with surgery; carmustine wafer; postoperative radiation; and procarbazine, lomustine, and vincristine chemotherapy. Neurosurg Q 15:167–171CrossRef LaRocca R, Glisson S, Hargis J, Petruska D, Villanueva W, Morassutti D, Horne D, Amin-Zimmerman F (2005) High-grade glioma treated with surgery; carmustine wafer; postoperative radiation; and procarbazine, lomustine, and vincristine chemotherapy. Neurosurg Q 15:167–171CrossRef
14.
Zurück zum Zitat McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH (2002) Management of tumor bed cysts after chemotherapeutic wafer implantation. report of four cases. J Neurosurg 96:941–945CrossRefPubMed McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH (2002) Management of tumor bed cysts after chemotherapeutic wafer implantation. report of four cases. J Neurosurg 96:941–945CrossRefPubMed
15.
Zurück zum Zitat McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583–588CrossRefPubMed McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583–588CrossRefPubMed
16.
Zurück zum Zitat McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO (2003) Risk factors for post-craniotomy surgical site infection after 1, 3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 36:759–765CrossRefPubMed McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO (2003) Risk factors for post-craniotomy surgical site infection after 1, 3-bis(2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 36:759–765CrossRefPubMed
18.
Zurück zum Zitat Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-oncol 88:353–357CrossRef Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-oncol 88:353–357CrossRef
19.
Zurück zum Zitat Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008 Oct 20. doi:10.1185/03007990802508180 Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008 Oct 20. doi:10.​1185/​0300799080250818​0
20.
Zurück zum Zitat Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1, 3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case matched cohort series. Neurosurgery 45:17–22CrossRefPubMed Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D (1999) Morbidity and survival after 1, 3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case matched cohort series. Neurosurgery 45:17–22CrossRefPubMed
21.
Zurück zum Zitat Tait MJ, Critchley GR (2006) Experience of revision craniotomy for debulking of high grade gliomas in 27 patients in a single UK centre, with and without insertion of carmustine wafers. Meeting of the Society of British Neurosurgeons, Preston, UK, 2006 Tait MJ, Critchley GR (2006) Experience of revision craniotomy for debulking of high grade gliomas in 27 patients in a single UK centre, with and without insertion of carmustine wafers. Meeting of the Society of British Neurosurgeons, Preston, UK, 2006
22.
Zurück zum Zitat Uff CEG, Bradford R (2005) Use of Gliadel (BCNU) Wafers in high grade glioma. Abstract presented at the meeting of the Society of British Neurosurgeons, Plymouth, UK, 2005 Uff CEG, Bradford R (2005) Use of Gliadel (BCNU) Wafers in high grade glioma. Abstract presented at the meeting of the Society of British Neurosurgeons, Plymouth, UK, 2005
23.
Zurück zum Zitat Volc D, Jellinger K, Flament H, Böck F, Klumair J (1981) Cerebral space-occupying cysts following radiation and chemotherapy of malignant gliomas. Acta Neurochir (Wien) 57:177–193CrossRef Volc D, Jellinger K, Flament H, Böck F, Klumair J (1981) Cerebral space-occupying cysts following radiation and chemotherapy of malignant gliomas. Acta Neurochir (Wien) 57:177–193CrossRef
24.
Zurück zum Zitat Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME (2007) Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 25:399–404CrossRefPubMed Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME (2007) Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 25:399–404CrossRefPubMed
25.
Zurück zum Zitat Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88PubMed Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88PubMed
Metadaten
Titel
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series
verfasst von
Alessandro Della Puppa
Marta Rossetto
Pietro Ciccarino
Giulia Del Moro
Antonino Rotilio
Renzo Manara
Marina Paola Gardiman
Luca Denaro
Domenico d’Avella
Renato Scienza
Publikationsdatum
01.11.2010
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica / Ausgabe 11/2010
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-010-0759-6

Weitere Artikel der Ausgabe 11/2010

Acta Neurochirurgica 11/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.